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Material and methods 
All manipulations requiring anhydrous conditions were carried out in flame-dried glassware, 
with magnetic stirring and under a nitrogen atmosphere. All commercially available reagents 
were used as received. Anhydrous solvents were purchased from commercial sources and 
withdrawn from the container by syringe, under a slight positive pressure of nitrogen. The 
reactions were monitored by analytical thin-layer chromatography (TLC) using Macherey-
Nagel 0.20 mm silica gel 60 with fluorescent indicator pre-coated polyester sheets (40 × 80 
mm). Visualization was accomplished by irradiation with a UV lamp and/or staining with 
cerium/molybdate reagent, ninhydrin or cinnamaldehyde. Automated chromatography was 
performed with Teledyne Isco CombiFlash Rf 150. Proton NMR spectra were recorded on a 
spectrometer operating at 400.16 MHz. Proton chemical shifts are reported in ppm (δ) with the 
solvent reference relative to tetramethylsilane (TMS) employed as the internal standard (D2O δ 
= 4.79 ppm). The following abbreviations are used to describe spin multiplicity: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, bs = broad signal, dd = doublet of doublet, ddd = 
doublet of doublet of doublet, ddt = doublet of doublet of triplet, td= triplet of doublet. Carbon 
NMR spectra were recorded on a spectrometer operating at 100.63 MHz, with complete proton 
decoupling. Carbon chemical shifts are reported in ppm (δ) relative to TMS with the respective 
solvent resonance as the internal standard. 
ESI–MS spectra were recorded on an ion trap mass spectrometer Finnigan LCQ Advantage or 
Micro Waters Q-Tof (ESI source) and on a Thermo Fisher linear ion trap LTQ XL mass 
spectrometer. The MALDI–TOF–MS spectra were recorded on a Bruker Microflex™ LT 
instrument, supporting the sample on α-cyano-4-hydroxycinnamic acid (HCCA) and sinapinic 
acid (SA) matrices. The peptide calibration standard (300–3000 Da range), which consisted of 
angiotensin II, angiotensin I, substance P, bombesin; ACTH clip 1-17, ACTH clip 18-39, 
somatostatin 28, was purchased from Bruker Daltonics® and used to calibrate the MALDI-
TOF-MS instrument. The sample was mixed in equal volumes with the matrix solution: a small 
amount (1 μL) of this mixture was spotted on the target surface. The target matrix was dried at 
room temperature and then analyzed. 
High-resolution mass spectra (HRMS) were performed with a Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass software (Bruker Daltonics) – 4.7 
T Magnet (Magnex) equipped with ESI source, available at CIGA (Centro Interdipartimentale 
Grandi Apparecchiature) c/o Università degli Studi di Milano. 
HPLC purifications and HPLC traces of final products were performed on Dionex Ultimate 
3000 equipped with Dionex RS Variable Wavelenght Detector (column: Atlantis Prep T3 
OBD
TM
 5 µm 19 × 100 mm; flow 15 mL/min unless stated otherwise). The crude reaction 
mixture was dissolved in H2O or, if the compound was insoluble in water, adding first DMF, 
then diluting slowly with H2O until reaching a 1:1 DMF/H2O ratio (an ultrasonic bath was used 
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to assist the dissolution). The solution obtained was filtered (polypropylene, 0.45 μm, 13 mm ø, 
PK/100) and injected in the HPLC, affording purified products. Purity analyses were carried on 
a Dionex Ultimate 3000 instrument equipped with a Dionex RS Variable Wavelenght detector 
(column: Atlantis® Prep T3 OBDTM 5 μm 19 × 100 mm). The analyte (1 mg) was dissolved in 
1 mL of H2O and was injected using the same gradient used in the purification step. The 
analysis of the integrals and the relative percentage of purity were performed with the software 
Chromeleon 6.80 SR11 Build 3161. Also, preparative HPLC LaPrep∑ equipped with 
autosampler AS3950 and a Phenomenex Luna C-18(2) column, 10 µm, 250 × 21.2 mm, with 
precolumn at 30 mL/min flow rate and analytical HPLC performed on Hitachi Chromaster 
(column oven Chromaster 5310, pump Chromaster 5110, autosampler Chromaster 5210, DAD 
Chromaster 5430) equipped with a Phenomenex Luna C-18(2) column, 10 µm, 250 × 4.6 mm, 
with precolumn at 1.4 mL/min flow rate were used. Freeze-drying: The product was dissolved 
in water and frozen with dry ice. The freeze-drying was carried out at least for 48 h at −50 °C 
using the instrument 5Pascal Lio5P DGT. 
 
Biological assays 
Solid phase receptor binding assays 
 
Recombinant human integrin V3 (R&D Systems, Minneapolis, MN, USA) was diluted to 0.5 
g/mL in coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl2, 2 
mM CaCl2, and 1 mM MgCl2. 100 Microliters of the diluted receptor (100 L/well) were added 
to 96-well microtiter plates (Nunc MaxiSorp) and incubated overnight at 4 °C. The plates were 
treated for additional 2 h at room temperature with blocking solution (coating buffer plus 1% 
bovine serum albumin) to block nonspecific binding, and washed 2 times with the same 
solution. Different concentrations (10
−5–10−12 M) of the test compounds in the presence of 1 
g/mL biotinylated vitronectin were added to the plates, which were shaken for 3 h at room 
temperature. Vitronectin,(Molecular Innovations, Novi, MI, USA) was biotinylated using an 
EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL, USA). The plates were washed 3 
times, and incubated with shaking for 1 h, at room temperature, with streptavidin-biotinylated 
peroxidase complex (Amersham Biosciences, Uppsala, Sweden). The plates were again washed 
3 times with blocking solution, and 100 L/well of Substrate Reagent Solution (R&D Systems, 
Minneapolis, MN, USA) were added before shaking in the dark for 30 min and stopping the 
reaction with the addition of 50 L/well 2 N H2SO4. Absorbance at 415 nm was read in a 
SynergyTM HT Multi-Detection Microplate Reader (BioTek Instruments, Inc.). Each data point 
represents the average of triplicate wells; data analysis was carried out by nonlinear regression 
analysis with GraphPad Prism software. Each experiment was repeated in triplicate. 
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Determination of integrin αVβ3 expression by flow cytometry 
 
The expression of integrin αVβ3 in U87-MG, A549 and MDA-MB 468 cells was determined by 
flow cytometry on a FACSCalibur device (Becton Dickinson). Before staining, cells were fixed 
with fixation solution (0.5% PFA in PBS). 5 × 10
5 
cells per
 
sample were stained in staining 
medium (PBS, 25 mM HEPES, 3% FCS, 0.02% Na-azide) with an anti-human integrin αVβ3 
antibody conjugated to Alexa Fluor 488 (R&D Systems) or isotype control conjugated to 
Alexa Fluor 488 (Thermo Fischer) at a concentration of 4 µg/mL for 45 min at room 
temperature. The cells were washed with PBS and the mean fluorescence intensity was 
measured for 10.000 gated events. The data were analyzed using flow cytometry and associated 
software (BD Biosciences) (Figure S1). 
Figure S1. Flow cytometry analysis of integrin αVβ3 expression in cancer cell lines. U87-MG: 
integrin αVβ3 overexpressed; A549 and MDA-MB 468: integrin αVβ3 negative.  
 
Cell culture 
 
All cell culture reagents were purchased at PAN-Biotech GmbH unless otherwise stated. Cell 
lines were obtained from CLS (U87-MG, MDA-MB 468 and A549). Cell lines were 
authenticated using Multiplex Cell Authentication by Multiplexion (Heidelberg, Germany) as 
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described recently.
[S1] 
The SNP profiles matched known profiles or were unique. The purity of 
the cell lines was validated using the Multiplex cell Contamination Test by Multiplexion 
(Heidelberg, Germany) as described recently.
[S2] 
No mycoplasma, SMRV or interspecies 
contamination was detected. U87-MG, MDA-MB 468 and A549 cells were cultivated 
continuously for not more than 3 months in MEM Eagle´s, DMEM or Ham´s F12 medium, 
respectively, supplemented with 10% heat inactivated fetus calf serum, L-glutamine and 
antibiotics. Cell lines were maintained at 37 ºC and 5% CO2 in a high humidity atmosphere. 
 
Cell therapy and viability assay 
 
Cell viability assays were performed in U87-MG, A549 and MDA-MB 468 cell lines according 
to the following procedure: 2 × 10
3 
cells/well were plated in 96-well black clear bottom plates 
(Perkin Elmer) and incubated overnight. 1:5 serial dilutions of compounds 7–11 were prepared 
in cell culture media. The compounds were added to the cell culture and incubated for additional 
96 h. Starting concentration of compounds 7–11 in the wells was 1 × 10−5 M and cell viability 
was determined with the CellTiterGlo 2.0 assay (Promega) in accordance to manufacturer’s 
instructions. The cell viability was calculated in relation to the non-treated controls for each cell 
line. All samples were measured in triplicate. Data analysis was carried out using software 
GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA).  
 
Competition experiment of compounds 10 and 11 
 
The competition experiments were performed in U87-MG and MDA-MB 468 cell lines 
according to the following procedure: 2 × 10
3 
cells/well were plated in 96-well black clear 
bottom plates (Perkin Elmer) and incubated overnight. A solution containing 1 × 10
−4 
M of the 
conjugates 10 or 11 and 5 × 10
−3
 M of cilengitide (50-fold excess of ligand in comparison to the 
conjugate) was prepared in the growth medium and 1:5 serial dilutions were prepared in cell 
culture media. The compounds were added to cell culture and incubated for 96 h. The starting 
concentration of the compounds in the wells was 0.01 mM whereas that of cilengitide was 0.5 
mM. The cell viability was determined with the CellTiterGlo 2.0 assay (Promega) in accordance 
to manufacturer’s instructions and the viability was calculated in relation to the non-treated 
controls for each cell line. All samples were measured in triplicate. Data analysis was carried 
out using software GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA).  
                                                          
[S1] F. Castro, W. G. Dirks, S. Fähnrich, A. Hotz-Wagenblatt, M. Pawlita, M. Schmitt, Int. J. Cancer 
2013, 132, 308–314. 
[S2] M. Schmitt, M. Pawlita, Nucleic Acids Res. 2009, 37, e119. 
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Synthesis of cyclo[DKP-RGD]-α-amanitin conjugates 7 and 9 
 
Synthesis of cyclo[DKP-RGD]-uncleavable-α-amanitin (7) 
 
 
 
Scheme S1. Synthesis of cyclo[DKP-RGD]-uncleavable-α-amanitin (7). Reagents and conditions: a) glutaric 
anhydride, DMAP, iPr2NEt, DMF, overnight, yield.: 77%; b) 1. DIC, N-hydroxysuccinimide, DMF, overnight, 2. 
NH2CH2-cyclo[DKP-RGD] (2), PBS/MeCN (pH 7.5), overnight, yield.: 46%. 
 
Hemiglutarate-aminohexyl-α-amanitin (15) 
 
 
 
 
 
Compound 12a (5 mg, 4.4 μmol, 1 equiv) was dissolved in 10 µL of DMF and cooled at 0 ºC 
under nitrogen conditions. Glutaric anhydride (1.26 mg, 11 μmol, 2.5 equiv), DMAP (0.13 mg, 
1.1 μmol, 0.25 equiv) and iPr2NEt (2.87 µL, 16.5 μmol, 3.75 equiv) were added as stock 
solutions in DMF and the reaction was stirred at 0 ºC for a few minutes. The mixture was then 
warmed to room temperature and stirred overnight under nitrogen atmosphere. The solvent was 
evaporated under high vacuum and the crude was purified by semipreparative HPLC [Waters 
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Atlantis 21 mm × 10 cm column; gradient: 100% (H2O + 0.1 % CF3COOH)/0% (CH3CN + 
0.1% CF3COOH) to 55% (H2O + 0.1 % CF3COOH)/45% (CH3CN + 0.1% CF3COOH) in 10 
minutes; tR: (product): 8.8 min]. The purified compound was then freeze-dried to affford 
compound 15 as a white solid (3.85 mg, 77% yield). 
1
H NMR (400 MHz, D2O) δ 8.70 (d, J = 9.8 Hz, 1H), 8.25 (d, J = 7.1 Hz, 1H), 7.77 (d, J = 8.9 
Hz, 1H), 7.10 (d, J = 2.0 Hz, 1H), 6.96 (dd, J = 8.9, 2.1 Hz, 1H), 5.26 (td, J = 11.4, 8.1 Hz, 1H), 
5.11 (dd, J = 12.8, 4.7 Hz, 1H), 5.00 (s, 1H), 4.74 (s, 1H), 4.67 – 4.61 (m, 2H), 4.26 – 4.09 (m, 
5H), 3.88 (d, J = 13.7 Hz, 1H), 3.82 (d, J =18.8 Hz, 2H), 3.77 – 3.71 (m, 5H), 3.67 – 3.52 (m, 
3H), 3.30 – 3.20 (m, 4H), 2.94 (dd, J = 14.6, 11.8 Hz, 1H), 2.58 – 2.50 (m, 1H), 2.49 –  2.41 (m, 
1H), 2.34 – 2.28 (m, 2H), 2.27 – 2.14 (m, 3H), 1.89 – 1.79 (m, 4H), 1.78 – 1.70 (m, 1H), 1.61 – 
1.48 (m, 5H), 1.47 – 1.38 (m, 2H), 1.29 – 1.19 (m, 1H), 1.03 (d, J = 7.0 Hz, 3H), 0.92 – 0.86 
(m, 6H); 
13
C NMR (101 MHz, D2O) δ 174.86, 174.17, 173.79, 173.27, 171.88, 171.65, 170.91, 
170.17, 168.65, 168.53, 157.00, 139.14, 127.40, 122.47, 121.38, 114.35, 111.87, 96.07, 72.73, 
69.84, 68.81, 63.36, 62.08, 59.91, 56.63, 55.73, 52.89, 51.60, 50.64, 42.58, 41.68, 39.12, 37.87, 
37.21, 34.85, 33.30, 32.69, 28.06, 25.44, 25.33, 24.76, 20.76, 14.12, 12.96, 9.80; MS (ESI+) m/z 
calcd. for [C50H74N11O17S]
+
: 1132.50 [M + H]
+
; found: 1132.87; m/z calcd. for 
[C50H73N11NaO17S]
+
: 1154.48 [M + Na]
+
; found: 1154.86; m/z calcd. for [C50H75N11O17S]
2+
: 
566.75 [M + 2H]
2+
; found: 566.95; m/z calcd. for [C50H74N11NaO17S]
2+
: 578.25 [M + 1H + 
Na]
2+
; found: 577.94. 
 
Cyclo[DKP-RGD]-uncleavable-α-amanitin (7) 
 
 
 
 
 
Compound 15 (7.58 mg, 6.7 μmol, 1 equiv) was dissolved in 175 µL of DMF and cooled at 0 ºC 
under a nitrogen atmosphere. N-hydroxysuccinimide (1.15 mg, 10 μmol, 1.5 equiv) and DIC 
(1.55 µL, 10 μmol, 1.5 equiv) were added as stock solutions in DMF and the reaction mixture 
was stirred at 0 ºC for a few minutes. The reaction was allowed to reach room temperature and 
stirred overnight under a nitrogen atmosphere. Volatiles were then removed in vacuo to give a 
solid, which was redissolved in acetonitrile (176 µL) and cooled to 0 ºC. A solution of NH2CH2-
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cyclo[DKP-RGD] (2) (2.88 mg, 3.35 μmol, 0.5 equiv) in phosphate buffer (211 µL, pH 7.5) was 
then added to the acetonitrile solution, and the pH value was adjust to 7.3–7.6 with NaOH (0.2 
M). The resulting solution was warmed to room temperature and stirred overnight. During the 
first hours, the pH was kept between 7.3–7.6 with NaOH (0.2 M), until a stable value was 
observed. The solution was concentrated, and the crude residue was purified by semipreparative 
HPLC [Waters Atlantis 21 mm × 10 cm column; gradient: 100% (H2O + 0.1% CF3COOH)/0% 
(CH3CN + 0.1% CF3COOH) to 50% (H2O + 0.1% CF3COOH)/ 50% (CH3CN + 0.1% 
CF3COOH) in 9 minutes; tR: (product): 8 min]. The purified compound was then freeze-dried to 
afford compound 7 as a white solid (2.87 mg, 46% yield). 
1
H NMR (400 MHz, D2O) δ 8.70 (s, 1H), 8.27 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.9 Hz, 1H), 
7.26 (m, 4H), 7.01 (d, J = 2.1 Hz, 1H), 6.88 (dd, J = 8.8, 2.1 Hz, 1H), 5.30 – 5.19 (m, 1H), 5.11 
(dd, J = 9.5, 4.7 Hz, 1H), 5.03 – 4.97 (m, 2H), 4.88 (t, J = 7.1 Hz, 1H), 4.75 (s, 1H), 4.68 – 4.61 
(m, 2H), 4.55 (dd, J = 7.9, 5.6 Hz, 1H), 4.39 – 4.04 (m, 11H), 4.00 – 3.79 (m, 3H), 3.79 – 3.48 
(m, 10H), 3.31 – 3.14 (m, 6H), 2.99 – 2.74 (m, 2H), 2.66 – 2.43 (m, 1H), 2.34 – 2.12 (m, 4H), 
2.05 – 1.87 (m, 2H), 1.85 – 1.70 (m, 3H), 1.71 – 1.60 (m, 1H), 1.57 – 1.44 (m, 4H), 1.43 – 1.33 
(m, 2H), 1.26 – 1.20 (m, 2H), 1.15 (d, J = 6.5 Hz, 8H), 1.04 (d, J = 7.0 Hz, 3H), 0.95 – 0.85 (m, 
6H). MS (MALDI-TOF): m/z calcd. for [C77H110N21O24S]
+
: 1745.89 [M + H]
+
; found: 1746.5 
(HCCA matrix), 1747.9 (SA matrix). 
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Synthesis of cyclo[DKP-RGD]-Val-Ala-α-amanitin (9) 
 
 
 
Scheme S2. Synthesis of cyclo[DKP-RGD]-Val-Ala-α-amanitin (9). Reagents and conditions: a) glutaric anhydride, 
DMAP, iPr2NEt, DMF, overnight, yield.: 98%; b) 1. DIC, N-hydroxysuccinimide, DMF, overnight, 2. NH2CH2-
cyclo[DKP-RGD] (2), PBS (pH 7.5), overnight, yield: 74%. 
 
Hemiglutarate-Val-Ala-α-amanitin (16) 
 
 
 
 
 
 
 
 
Compound 12b (5 mg, 3.9 μmol, 1 equiv) was cooled to 0 ºC under a nitrogen atmosphere. 
Glutaric anhydride (0.65 mg, 5.7 μmol, 1.5 equiv), DMAP (0.12 mg, 0.9 μmol, 0.25 equiv) and 
iPr2NEt (1 µL, 5.7 μmol, 1.5 equiv) were added as stock solutions in DMF and the reaction was 
stirred at 0 ºC for a few minutes. Then the mixture was warmed to room temperature and stirred 
overnight under a nitrogen atmosphere. The solvent was evaporated under high vacuum and the 
crude was purified by semipreparative HPLC [Waters Atlantis 21 mm × 10 cm column; 
gradient: 100% (H2O + 0.1 % CF3COOH)/0% (CH3CN + 0.1% CF3COOH) to 50% (H2O + 
0.1% CF3COOH)/50% (CH3CN + 0.1% CF3COOH) in 9 minutes; tR: (product): 8.6 min]. The 
purified compound was then freeze-dried to afford compound 16 as a white solid (4.92 mg, 98% 
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yield). MS (MALDI-TOF): m/z calcd. for [C59H82N13O19S]
+
: 1309.42 [M + H]
+
; found: 1309 
(SA matrix);  m/z calcd. for [C59H81N13NaO19S]
+
: 1331.40 [M + Na]
+
; found: 1331.7 (HCCA 
matrix), 1331 (SA matrix); m/z calcd. for [C59H81N13Na2O19S2]
2+
: 1354.39 [M + 2 Na]
2+
; found: 
1353.7 (HCCA matrix), 1353 (SA matrix). 
 
Cyclo[DKP-RGD]-Val-Ala-α-amanitin (9) 
 
 
 
 
 
 
 
 
 
Compound 16 (8.46 mg, 6.5 μmol, 1 equiv) was dissolved in 80 µL of DMF and cooled at 0 ºC 
under nitrogen conditions. N-Hydroxysuccinimide (1.11 mg, 9.7 μmol, 1.5 equiv) and DIC (1.5 
µL, 9.7 μmol, 1.5 equiv) were added (the two incorporated reagents were prepared as stock 
solutions in DMF) and the reaction was stirred at 0 ºC for a few minutes. Then the mixture was 
warmed to room temperature and stirred overnight under a nitrogen atmosphere. Volatiles were 
then removed in vacuo to give a solid, which was re-dissolved in PBS (210 µL, pH 7.5) and 
DMF (30 µL) and cooled to 0 ºC. A solution of NH2CH2-cyclo[DKP-RGD] (2) (2.78 mg, 3.23 
µL, 0.5 equiv) in phosphate buffer (150 µL, pH 7.5) was then added to the previous solution, 
and the pH was adjusted to 7.3–7.6 by adding small aliquots of aqueous NaOH (0.2 M) during 
the first hours of reaction, until a stable value was observed. The solution was concentrated, and 
the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm × 10 cm 
column; flow: 15 mL/min, gradient: 100% (H2O + 0.1% CF3COOH)/0% (CH3CN + 0.1% 
CF3COOH) to 50% (H2O + 0.1% CF3COOH)/50% (CH3CN + 0.1% CF3COOH) in 9 minutes; 
tR: (product): 8.3 min]. The purified compound was then freeze-dried to afford compound 9 as a 
white solid (4.85 mg, 74% of yield). 
MS (ESI+) m/z calcd. for [C86H119N23O26S]
2+
: 960.92 [M + 2H]
2+
; found: 960.76; m/z calcd. for 
[C86H118N23NaO26S]
2+
: 971.91 [M + Na + H]
2+
; found: 972.23; m/z calcd. for 
[C86H117N23Na2O26S]
2+
: 982.9 [M + 2Na]
2+
; found: 982.74; HRMS (ESI+): m/z calcd. for 
[C86H118N23NaO26S]
2+
: 971.91 [M + Na + 1H]
2+
; found: 971.91; m/z calcd. for 
[C86H117N23Na2O26S]
2+
: 982.90 [M + 2Na]
2+
; found: 982.90; m/z calcd. for 
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[C86H116N23Na3O26S]
2+
: 993.89 [M + 3Na - H]
2+
; found: 993.89; m/z calcd. for 
[C86H117N23Na3O26S]
3+
: 662.93 [M + 3Na]
3+
; found: 662.93. 
 
Synthesis of cyclo[DKP-isoDGR]-α-amanitin conjugates 8, 10 and 11 
 
Synthesis of cyclo[DKP-isoDGR]-uncleavable-α-amanitin (8) 
 
 
 
Scheme S3. Synthesis of cyclo[DKP-isoDGR]-uncleavable-α-amanitin (9). Reagents and conditions: a) di-N-
succinimidyl glutarate, iPr2NEt, DMF, 6 hours, yield: 90%; b) NH2CH2-cyclo[DKP-isoDGR] (4), PBS (pH 7.5), 
overnight, yield: 45%. 
 
Glutarate NHS ester-aminohexyl-α-amanitin (13a) 
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Compound 12a (11 mg, 10.9 µmol, 1 equiv) was dissolved in 150 µL of dry DMF under 
nitrogen atmosphere. The solution was cooled to 0 °C, then di-N-succinimidyl glutarate (4 mg, 
12 µmol. 1.1 equiv) and DIPEA (2 µL, 12 µmol, 1.1 equiv) were added and the mixture was 
stirred at room temperature for 6 hours. The reaction was monitored by TLC 
(CHCl3/MeOH/water 65:25:4, cinnamaldehyde staining). The crude was poured into 10 mL 
precooled MTBE placed in a 10 mL centrifugal tube (the reaction flask was rinsed with 3 × 50 
µL of DMF and each rinsing solution was transferred to the MTBE tube). The tube was sealed, 
vortexed and placed in ice for 10 min. The tube was spun for 3 min at 4500 RPM in a pre-
cooled centrifuge. The supernatant was transferred to a 50 mL flask. The pellet was suspended 
again into 10 mL of MTBE by vortexing and sonication. The tube was placed in ice for 10 mins 
and the centrifugation was repeated, then the pellet was dried in vacuo. The combined MTBE 
phases were concentrated under reduced pressure and checked for remaining product by TLC 
and HPLC. The dried pellet was used in the next step without further purification (12 mg, 90% 
yield).  
 
Cyclo[DKP-isoDGR]-uncleavable-α-amanitin (8) 
 
 
 
 
 
 
 
 
 
 
 
A solution of 4 (5.0 mg, 5.8 µmol, 1 equiv) in 150 µL of PBS was added to a solution of 13a 
(12 mg, 10 µmol, 1.7 equiv) in 150 µL of DMF at 0 °C. The pH was adjusted to 7.3–7.6 by 
adding small aliquots of aqueous NaOH (0.2 M) during the first hours of reaction, until a stable 
value was observed, and then the reaction mixture was stirred overnight at room temperature.  
The solution was directly filtered into a 3 mL vial and purified by preparative HPLC (gradient: 
from 95% (H2O + 0.05% CF3COOH)/5% CH3CN to 60% (H2O + 0.05% CF3COOH)/40% 
CH3CN in 14.5 mins), tR (product): 8.8 min. The purified product was freeze-dried to give the 
final product as a white solid (4.5 mg, 45% yield). MS (ESI+): m/z calcd. for 
[C77H110N21O24S]
+
= 1744.77 [M + H]
+
, found: 1745,67. 
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Synthesis of cyclo[DKP-isoDGR]-Val-Ala-α-amanitin (10) 
 
 
Scheme S4. Synthesis of cyclo[DKP-isoDGR]-Val-Ala-α-amanitin (10). Reagents and conditions: a) di-N-
succinimidyl glutarate, iPr2NEt, DMF, 6 hours, yield.: 71%; b) NH2CH2-cyclo[DKP-isoDGR] (4), PBS (pH 7.5), 
overnight, yield.: 62%. 
 
Glutarate NHS ester-Val-Ala- α-amanitin (13b) 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 12b (10 mg, 8.3 µmol, 1 equiv) was dissolved in 150 µL of dry DMF under nitrogen 
atmosphere. The solution was cooled to 0 °C, then di-N-succinimidyl glutarate (3.2 mg, 9.9 
µmol, 1.2 equiv) and DIPEA (1.6 µL, 9.1 µmol, 1.1 equiv) were added and the mixture was 
stirred at room temperature for 6 hours. The reaction was monitored by TLC 
(CHCl3/MeOH/water 65:25:4, cinnamaldehyde staining). The crude was poured into 10 mL pre-
cooled MTBE placed in a 10 mL centrifugal tube (the reaction flask was rinsed with 3 × 50 µL 
of DMF and each rinsing solution was transferred to the MTBE tube). The tube was sealed, 
vortexed and placed in ice for 10 min. The tube was spun for 3 min at 4500 RPM in a precooled 
centrifuge. The supernatant was transferred to a 50 mL flask. The pellet was suspended again 
into 10 mL of MTBE by vortexing and sonication. The tube was placed on ice for 10 mins and 
the centrifugation was repeated. Then the pellet was dried in vacuo. The combined MTBE 
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phases were concentrated under reduced pressure and checked for remaining product by TLC 
and HPLC. The dried pellet was used in the next step without further purification (8.3 mg, 71% 
yield).  
 
 
Cyclo[DKP-isoDGR]-Val-Ala-α-amanitin (10) 
 
 
 
 
 
 
 
 
 
 
A solution of 4 (3.4 mg, 3.9 µmol, 1 equiv) in 150 µL of PBS was added to a solution of 13b 
(8.3 mg, 5.9 µmol, 1.5 equiv) in 150 µL of DMF at 0 °C. The pH was adjusted to 7.3–7.6 by 
adding small aliquots of aqueous NaOH (0.2 M) during the first hours of reaction (until a stable 
value was observed), then the reaction mixture was stirred overnight at room temperature. The 
solution was directly filtered into a 3 mL vial and purified by preparative HPLC (gradient: from 
95% (H2O + 0.05 % CF3COOH)/5% CH3CN to 60% (H2O + 0.05% CF3COOH)/40% CH3CN in 
14.5 min), tR (product): 9.2 min. The purified product was freeze-dried to give the final product 
as a white solid (4.8 mg, 62% yield). MS (ESI+): m/z calculated for [C86H118N23O26S]
+
= 1921.05 
[M + H]
+
, found: 1921.75. 
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Synthesis of cyclo[DKP-isoDGR]-PEG-4-Val-Ala-α-amanitin (11) 
 
 
 
Scheme S5. Synthesis of cyclo[DKP-isoDGR]-PEG-4-Val-Ala-α-amanitin (11). Reagents and conditions: a) 4-
pentynoic acid NHS ester (17), iPr2NEt, DMF/DCM, overnight, yield.: 88 %; b) N3-PEG-4-cyclo[DKP-isoDGR] 
(18), DMF/water 1/1, sodium ascorbate, CuSO4·7H2O, overnight, yield: 62%. 
 
4-Pentynoic acid NHS ester (17) 
 
 
 
 
 
 
 
 
4-Pentynoic acid (10 mg, 0.100 mmol, 1 equiv) was dissolved in 2 mL of dry DCM under argon 
and cooled to 0 °C. EDC·HCl (23 mg, 0.120 mmol, 1.2 equiv) and NHS (14 mg, 0.120 mmol, 
1.2 equiv) were sequentially added to the solution and the reaction mixture was stirred overnight 
at room temperature. The mixture was diluted in 20 mL of DCM and the organic phase was 
washed with water (3 × 7 mL), dried over MgSO4, filtrated and concentrated under reduced 
pressure to give the product as a yellowish oil that was used in next step without further 
modifications. 
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4-Pentynoic acid-Val-Ala-α-amanitin (14) 
 
 
  
 
  
 
 
 
 
 
 
 
Under argon, DIPEA (1 µL, 6.3 µmol, 1.5 equiv) and compound 17 dissolved in DCM (200 µL) 
were added to a solution of compound 12b (5.0 mg, 4.2 µmol, 1 equiv) in 200 µL of DMF kept 
at 0 °C. The reaction mixture was stirred overnight at room temperature. Volatiles were 
evaporated under reduced pressure and the crude was dissolved in 500 µL of MeOH and then 
purified by preparative HPLC (gradient: from 95% (H2O + 0.05% CF3COOH) / 5% (CH3CN) to 
0% (H2O + 0.05% CF3COOH)/100% (CH3CN) in 15 mins), tR product = 7.97 min. The 
collected fraction was concentrated under reduced pressure and freeze-dried from water/ACN 
1/1 to afford the product as a white solid (4.7 mg, 88% yield). MS (ESI+): m/z calculated for 
[C59H80N13O17S]
+
= 1273.54 [M + H]
+
, found: 1274.55. 
 
14-Azido-3,6,9,12-tetraoxatetradecanoic acid NHS ester (19) 
 
 
 
 
100 µL (0.05 mmol, 1 equiv) of a 0.5 M solution of 14-azido-3,6,9,12-tetraoxatetradecanoic acid 
(~0.5 M in tert-butyl methyl ether) were diluted in 100 µL of dry DCM under argon and cooled 
to 0 °C. EDC·HCl (12,5 mg, 0.065 mmol, 1.3 equiv) and NHS (7.5 mg, 0.065 mmol, 1.3 equiv) 
were sequentially added to the solution and the reaction mixture was stirred overnight at room 
temperature. The mixture was diluted in 10 mL of DCM and the organic phase was washed with 
water (3 × 3 mL), dried over MgSO4, filtrated and concentrated under reduced pressure to give 
the product as a transparent oil (18.2 mg, 97% yield). The crude product was used in the next 
step without further modifications. 
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N3-PEG-4-cyclo[DKP- isoDGR] (18) 
 
 
 
 
 
 
 
 
To a solution of compound 19 (9.2 mg, 24 µmol, 2 equiv) in 500 µL of ACN was added 
H2NCH2-cyclo[DKP-isoDGR] (4, 10.5 mg, 12 µmol, 1 equiv) dissolved in 500 µL of PBS (pH 
7) was added. The pH was adjusted to 7.4 with a solution of NaOH (0.2 M) and the reaction was 
stirred overnight at room temperature. The mixture was filtered into a 3 mL vial, centrifuged 
and purified by preparative HPLC (gradient: from 95% (H2O + 0.05% CF3COOH)/5% CH3CN) 
to 60% (H2O + 0.05% CF3COOH)/40% CH3CN in 14.5 min, tR product = 8.3 min). The 
collected fraction was concentrated under reduced pressure and freeze-dried from 1:1 
water/CH3CN to afford the product as a white solid (5.5 mg, 46% yield). MS (ESI+): m/z 
calculated for [C37H56N13O13]
+
= 890.41 [M + H]
+
, found: 890.50. 
 
Cyclo[DKP-isoDGR]-PEG-4-Val-Ala- α-amanitin (11) 
 
 
To a solution of 14 (2.9 mg, 2.3 µmol) in 1 mL of DMF at 0 °C, compound 16 (2.7 mg, 2,7 
µmol) dissolved in 1 mL of water, sodium ascorbate (0.2 mg, 0.88 µmol) and CuSO4·7 H2O 
(0.25 mg, 0.44 µmol) were sequentially added. The solution, which turned light yellow, was 
stirred overnight at room temperature until the color changed to light blue. 
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Volatiles were evaporated under reduced pressure and the crude was re-dissolved in 400 µL of 
MeOH, filtered and purified by preparative HPLC (gradient: from 95% (H2O + 0.05% 
CF3COOH)/5% (CH3CN + 0.05% CF3COOH) to 0% (H2O + 0.05% CF3COOH)/100% (CH3CN 
+ 0.05% CF3COOH) in 15 min, tR product = 7.2 min). The collected fraction was concentrated 
under reduced pressure and freeze-dried from 1:1 water/CH3CN to afford the product as a white 
solid (3.33 mg, 62% yield). MS (ESI+): m/z calculated for [C96H136N26O30S2]
2+
= 1082.48 [M + 
2H]
2+
, found: 1082.92. 
 
HPLC traces of the final compounds 
 
Cyclo[DKP-RGD]-uncleavable-α-amanitin (7) 
 
Waters Atlantis 21 mm × 10 cm column; gradient: 100% (H2O + 0.1% CF3COOH)/0% (CH3CN 
+ 0.1% CF3COOH) to 50% (H2O + 0.1% CF3COOH)/ 50% (CH3CN + 0.1% CF3COOH) in 9 
minutes; tR: (product): 8 min. 
Purity: 95%. 
 
 
 
Cyclo[DKP-isoDGR]-uncleavable-α-amanitin (8) 
 
Phenomenex Luna C-18(2) column 10 µm, 250 × 21.2 mm, with precolumn at 30 mL/min flow 
rate; gradient: 95% (H2O + 0.05% CF3COOH)/5% CH3CN to 60% (H2O + 0.05% 
CF3COOH)/40% CH3CN in 14.5 mins, tR (product): 8.8 min. 
Purity: 96.2% 
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Cyclo[DKP-RGD]-Val-Ala-α-amanitin (9) 
 
Waters Atlantis 21 mm × 10 cm column; flow: 15 mL/min, gradient: 100% (H2O + 0.1% 
CF3COOH)/0% (CH3CN + 0.1% CF3COOH) to 50% (H2O + 0.1% CF3COOH)/50% (CH3CN + 
0.1% CF3COOH) in 9 minutes; tR: (product): 8.3 min. 
 
Purity: 99.6%. 
 
 
 
Cyclo[DKP-isoDGR]-Val-Ala-α-amanitin (10) 
 
Phenomenex Luna C-18(2) column 10 µm, 250 × 21.2 mm, with precolumn at 30 mL/min flow 
rate; gradient: 95% (H2O + 0.05% CF3COOH)/5% CH3CN to 60% (H2O + 0.05% 
CF3COOH)/40% CH3CN in 14.5 mins, tR (product): 9.2 min. 
Purity: 100%. 
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Cyclo[DKP-isoDGR]-PEG-4-Val-Ala- α-amanitin (11) 
 
Phenomenex Luna C-18(2) column 10 µm, 250 × 21.2 mm, with precolumn at 30 mL/min flow 
rate; gradient: 95% (H2O + 0.05% CF3COOH)/5% CH3CN to 100% CH3CN in 15 mins, tR 
(product): 7.2 min 
Purity: 89.9% 
 
 
ESI–MS, MALDI–TOF–MS and HRMS Spectra 
α-Amanitin-aminohexyl-hemiglutarate (15) 
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Cyclo[DKP-RGD]-uncleavable-α-amanitin (7) 
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α-Amanitin-aminohexyl-hemiglutarate (16) 
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Cyclo[DKP-RGD]-Val-Ala-α-amanitin (9) 
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Cyclo[DKP-isoDGR]-uncleavable-α-amanitin (8) 
 
 
 
Cyclo[DKP-isoDGR]-Val-Ala-α-amanitin (10) 
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Cyclo[DKP-isoDGR]-PEG-4-Val-Ala- α-amanitin (11) 
 
 
 
1H NMR and 13C NMR spectra 
α-Amanitin-aminohexyl-hemiglutarate (15) 
 
1
H NMR (400 MHz, D2O) 
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13
C NMR (101 MHz, D2O) 
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Cyclo[DKP-RGD]-uncleavable-α-amanitin (7) 
 
1
H NMR (400 MHz, D2O) 
 
 
